SER - NYSE
Serina Therapeutics, Inc.
$5.00
+0.0000%Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
At a Glance
Live SnapshotSerina Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Serina Therapeutics, Inc. Cash Flow Statement
SER • NYSE
| Serina Therapeutics, Inc. Cash Flow Statement | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||
-11.2M | 5.3M | -2.7M | -1.3M | -10.4M | -12.2M | -7.5M | -6.6M | -15.5M | |
194K | 90K | 61.3K | 33.4K | 1.3M | 951K | 535K | 682K | 845K | |
0.0 | 0.0 | 401.8K | -225.4K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
2.6M | 25K | 7.1K | 82.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-5.4M | -7.9M | 148.3K | -122.2K | 1.6M | 1.5M | -793K | -388K | 5.4M | |
-3.3M | 81K | -11.9K | -754.8K | -260K | -410K | 211K | 776K | 1.3M | |
-17.1M | -2.5M | -2.1M | -2.3M | -7.8M | -10.2M | -8M | -6.3M | -8.4M | |
INVESTING ACTIVITIES | |||||||||
-22K | -504K | -9.7K | -108.4K | -20K | -641K | -1.9M | -1K | -23K | |
(0.0) | (0.0) | (0.0) | (466K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | (0.0) | -666K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 990.6K | 931.8K | 0.0 | 354K | 3.2M | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 200K | 0.0 | -74K | 5K | 6K | -5K | |
-22K | -504K | (980.9K) | (823.3K) | -20K | -361K | (1.3M) | (5K) | -28K | |
FINANCING ACTIVITIES | |||||||||
5M | 15K | 4.4K | 0.0 | 0.0 | 4.5M | 6M | 12M | 2.4M | |
2.9M | 10.1M | 1.3M | -12.9K | 6M | 1.8M | 0.0 | 0.0 | 0.0 | |
5.3M | 0.0 | 0.0 | 1M | 0.0 | 0.0 | 0.0 | 1.3M | 4.8M | |
13.2M | 10.1M | 1.3M | 1.1M | 6M | 6.3M | 6M | 13.3M | 7.3M | |
CASH FLOW SUMMARY | |||||||||
0.0 | 0.0 | 0.0 | 0.0 | 51K | -99K | 0.0 | 0.0 | 0.0 | |
-3.9M | 7.1M | 217.4K | -350.2K | -1.8M | -4.4M | -668K | 7.1M | -1.2M | |
7.6M | 532K | 314.8K | 665.1K | 2.4M | 6.7M | 7.4M | 259K | 1.5M | |
3.7M | 7.6M | 532.2K | 314.8K | 527K | 2.4M | 6.7M | 7.4M | 259K | |
-17.2M | -3M | -2.1M | -2.4M | -7.8M | -10.8M | -9.9M | -6.3M | -8.5M |
SEC Filings
SER - Filing history and reports
No SEC filings available for SER
Related Guides
Continue your SER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.